Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-07-09
1999-03-16
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 9, 514 2, 530317, 530321, A61K 3012, C07K 764
Patent
active
058830758
ABSTRACT:
Disclosed are (1) a cyclic hexapeptide represented by formula I or a salt thereof: ##STR1## wherein X and Y each represent .alpha.-amino acid residues, A represents a D-acidic-.alpha.-amino acid residue, B represents a neutral-.alpha.-amino acid residue, C represents an L-.alpha.-amino acid residue and D represents a D-.alpha.-amino acid residue having an aromatic ring group; and (2) a pharmaceutical composition comprising the peptide represented by formula I or a pharmaceutically aceptable salt thereof as an active ingredient.
REFERENCES:
patent: 5114918 (1992-05-01), Ishikawa et al.
patent: 5260276 (1993-11-01), Cody et al.
K. Ishikawa et al., "Endothelin antagonistic cyclic pentapeptides with high selectivity for Et.sub.A receptor." Editors: Smith et al., Peptides, Chemistry and Biology, pp. 812-813, ESCOM; Leiden, Holland, 1992.
T. Saeki et al., "Endothelin-1 Analogs with ET.sub.B Agonistic Activity." Editors: Abelson et al., Biochemical and Biophysical Research Communications, vol. 179, No. 1, Academic Pres, Inc., 1991, pp. 286-292.
Y. Hirata et al., "Receptor Binding Activity and Cytosolic Free Calcium Response By Synthetic Endothelian Analogs in Cultured Rat Vascular Smooth Muscle Cells." Editors: Abelson et al., Biochemical and Biophysical Research Communications, vol. 160, Academic Press, Inc., 1989, pp. 228-234.
K. Nakajima et al., "Structure-Activity Relationship of Endothelin: Importance of Charged Groups" Editors: Abelson et al. Biochemical and Biophysical Research Communications, vol. 163, Academic Press, Inc., 1989, pp. 424-429.
S. Kimura et al. "Structure-Activity Relationships of Endothelin: Importance of the C-Terminal Moiety." Editors: Abelson et al. Biochemical and Biophysical Research Communications, vol. 156, No. 3, Academic Press, Inc., 1988, pp. 1182-1186.
WO 9202546-A1--Abstract.
Japanesse Patent No. 3-94692/91--Abstract.
Japanese Patent No. 3-130299/91--Abstract.
Japanese Patent No. 3-17098/91--Abstract.
Japanese Patent No. 3-141295/91--Abstract.
WO 9202546-A1.
A. Doherty, "Endothelin: A New Challenge." Journal of Medicinal Chemistry, vol. 35, No. 9, 1992, pp. 1493-1508.
M. Ihara et al., "Biological Profiles of Highly Potent Novel Endothelin Antagonists Selective for the ET.sub.A Receptor", Life Sciences, vol. 50, pp. 247-255, Pergamon Press, 1991.
EPO Search Report dated May 4, 1993, in corresponding case U.S. Ser. No. 07/927,205, submitted on Jun. 17, 1993.
Watanabe, et al., "Contribution of Endogeneous Endothelin to the Extension of Myocardial Infarct Size in Rats", Circulation Research, vol. 69, NO. 2, Aug. 1991, pp. 370-377.
M. Ihara et al., "An Endothelin Receptor (ET.sub.A) Antagonist isolated from Streptomyces Misakiensis." Editors: Abelson et al., Biochemical and Biophysical Research Communications, vol. 178, No. 1, Academic Press, Inc., 1991, pp. 132-137.
Kawada Akira
Kikuchi Takashi
Shirafuji Hideo
Wakimasu Mitsuhiro
Achutamurthy Ponnathapura
Conlin David G.
Lowen Cara Z.
Neuner George W.
Takeda Chemical Industries Ltd.
LandOfFree
Cyclic endothelin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic endothelin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic endothelin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-817794